NPI-0052 and Vorinostat in Patients With Non-Small Cell Lung Cancer, Pancreatic Cancer or Melanoma

Trial Profile

NPI-0052 and Vorinostat in Patients With Non-Small Cell Lung Cancer, Pancreatic Cancer or Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs Marizomib (Primary) ; Vorinostat
  • Indications Lymphoma; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Nereus Pharmaceuticals; Triphase Accelerator Corporation
  • Most Recent Events

    • 24 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Feb 2013 Planned end date changed from 1 Sep 2009 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 01 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top